CD40 and neoplasm: However, in situ, the priming of anti-cancer immunity by APCs may be hampered in HCC, since intra-tumoural activated DCs showed less expression of CD40 when compared to adjacent tissues in the majority of patients, especially in those with tumour suppressor gene mutations (183, 184).